Soligenix, Inc.
As of Oct 22, 2026, Soligenix is in Stage 4, the downtrend phase, now in week 49 (since Nov 3, 2025). It closed at $0.36, 78.2% below its 52-week high and below its 200-day average, which is falling.
Soligenix, Inc., a late-stage biopharmaceutical company, focuses on the development and commercialization of products to treat rare diseases in the United States. More about the company
Pro read
ProOur read
Setup score
Momentum
Edge
Is SNGX early, or has it already run? Pro answers that for every US stock we cover, after every close.
Renews monthly until you cancel. Cancel any time in Plan & billing.
SNGX among Biotechnology453rd of 591 by relative strength
All 591 →| # | Stock | Stage | RS | 1M |
|---|---|---|---|---|
| 1 | GTBP | Stage 2 · wk 7 | 99 | −22.3% |
| 2 | IOVA | Stage 2 · wk 18 | 99 | +38.8% |
| 3 | SLS | Stage 3 · wk 4 | 99 | −1.5% |
| 4 | MRNA | Stage 2 · wk 17 | 99 | +11.3% |
| 5 | TWST | Stage 2 · wk 39 | 99 | −14.5% |
| 6 | KOD | Stage 2 · wk 4 | 99 | +172.1% |
| 7 | ERAS | Stage 3 · wk 5 | 99 | +0.7% |
| 8 | CLYM | Stage 3 · wk 3 | 99 | −15.8% |
| …453 | SNGX | Stage 4 · wk 49 | 12 | −7.7% |
Soligenix: quick answers
What stage is Soligenix in?
As of Oct 22, 2026, Soligenix (SNGX) is in Stage 4, the downtrend phase. It entered Stage 4 on Nov 3, 2025 and is in week 49. What the four stages mean
Is Soligenix in an uptrend?
No. Soligenix is in a Stage 4 downtrend. It trades 49.4% below its 200-day average, which is falling.
How far is Soligenix from its 52-week high?
Soligenix closed at $0.36 on Oct 22, 2026, 78.2% below its 52-week high of $1.65. Its 52-week low is $0.28.
How has Soligenix performed over the past year?
As of Oct 22, 2026, Soligenix is down 78.2% over the past year and down 74.6% so far in 2026.
Which sector and industry is Soligenix in?
Soligenix is in the Biotechnology industry, part of the Health Care sector.
About this companyHealth Care· Biotechnology
Soligenix, Inc., a late-stage biopharmaceutical company, focuses on the development and commercialization of products to treat rare diseases in the United States. The company operates through two segments, Specialized BioTherapeutics and Public Health Solutions. The Specialized BioTherapeutics segment develops SGX301 (HyBryte), a photodynamic therapy, which has completed Phase 3 clinical trial for the treatment of cutaneous T-cell lymphoma; SGX942, an innate defense regulator (IDR) technology that is in Phase 3 clinical trial for the treatment of inflammatory diseases, including oral mucositis in head and neck cancer; SGX945, an IDR technology that is in Phase 2a study to treat aphthous ulcers in Behçet's disease; and SGX302, an IDR technology, which is in Phase 2a study for the treatment of mild-to-moderate psoriasis. Its Public Health Solutions segment engages in the development of RiVax, a ricin toxin vaccine candidate, which has completed Phase 1a, 1b, and 1c clinical trials; SGX943, a therapeutic candidate in preclinical studies for the treatment of antibiotic-resistant and emerging infectious diseases; ThermoVax, a technology in pre-clinical development for thermostabilizing vaccines; CiVax, a vaccine candidate for the prevention of COVID-19; and vaccine programs that target filoviruses, such as Marburg and Ebola. The company was formerly known as DOR BioPharma, Inc. and changed its name to Soligenix, Inc. in September 2009. Soligenix, Inc. was incorporated in 1987 and is headquartered in Princeton, New Jersey.
Visit company website →All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.